In a next phase, the dashboard will be expanded to provide information on progress towards the COVAX facility`s goal of obtaining 2 billion doses of vaccine by the end of 2021. It will also provide information on the status of procurement and supplies by UNICEF and other national and institutional buyers participating in the COVAX Facility. In a statement, Valneva said: "Valneva has worked tirelessly and to the best of its ability to work with the UK government, including investing significant resources and efforts to meet the UK government`s demands for variant-based vaccines. Quote: Centre for Global Health. (2021). COVID-19 Vaccine Purchase and Manufacturing Agreements. Institute of International and Development Studies. Excerpt from: www.knowledgeportalia.org/covid19-vaccine-arrangements VLA2001, a whole, inactivated, adjuvant vaccine candidate, is being studied in a study on Covid-19 in Europe. Valneva has worked tirelessly and to the best of its ability to work with HMG, including investing significant resources and effort to meet HMG`s demands for variant-based vaccines.

Valneva remains committed to the development of VLA2001 and will intensify its efforts with other potential customers to ensure that its inactivated vaccine can be used in the fight against the pandemic. The COVID-19 Vaccines Market Dashboard provides transparency and visibility to gain insights into the COVID-19 vaccine market. In this first version, the tool provides an overview of the vaccines under development, their stage of development and their technological platforms. In addition, information on globally reported production capacity as well as bilateral and multilateral supply agreements and publicly announced prices will be provided. The Company believes the vaccine will receive preliminary approval later this year, subject to Phase III data and the acquiescence of the MHRA. About VLA2001 VLA2001 is currently the only adjuvant vaccine candidate inactivated for the entire virus in COVID-19 clinical trials in Europe. It is intended for active immunization of at-risk populations to prevent promotion and symptomatic infection with COVID-19 during the ongoing pandemic and possibly later for routine vaccination, including treatment of new variants. VLA2001 may also be suitable for the increase, as repeated booster injections have been shown to work well with inactivated vaccines of the entire virus. VLA2001 is produced on Valneva`s established Vero cellular platform and uses Valneva`s licensed IXIARO® Japanese encephalitis vaccine manufacturing technology.

VLA2001 consists of whole inactivated sarS-CoV-2 virus particles with high density of S proteins, in combination with two excipients, alum and CpG 1018. This adjuvant combination consistently induced higher antibody levels than pure alum formulations in preclinical experiments and showed a change in the immune response to Th1. CpG 1018 adjuvant, supplied by Dynavax Technologies Corporation (Nasdaq: DVAX), is a component of the HEPLISAV-B vaccine® approved by the U.S. FDA and EMA. The manufacturing process of VLA2001, which has already been extended to the final industrial scale, involves chemical inactivation to preserve the native structure of the S protein. VLA2001 should meet the standard requirements of the cold chain (2 to 8 degrees Celsius). Forward-Looking Statements This press release contains certain forward-looking statements regarding Valneva`s operations, including progress, timing, design, data readings, expected results and completion of clinical trials for VLA2001. Although Valneva`s actual results or developments are consistent with the forward-looking statements contained in this press release, such results or developments of Valneva may not be indicative of future results. In some cases, you may identify forward-looking statements by words such as "could", "should", "may", "expects", "anticipates", "believes", "intends", "estimates", "aims", "targets" or similar words. These forward-looking statements are based on Valneva`s current expectations as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that could cause actual results, performance or achievements to differ materially from future results, performance or achievements expressed or implied by such forward-looking statements. can be brought.

In particular, Valneva`s expectations could be affected, among other things, by uncertainties related to vaccine development and manufacturing, unexpected results of clinical trials, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, the ability to obtain or maintain patents or other protected intellectual property protections. the termination of existing contracts, including, but not limited to, HMG`s supply agreement, and the impact of the COVID-19 pandemic, the occurrence of which could significantly affect Valneva`s business, financial condition, prospects and results of operations. Given these risks and uncertainties, there can be no assurance that any forward-looking statements made in this presentation will be effectively implemented. Valneva provides the information contained in this press release as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. After all, through bilateral agreements, low-income countries have obtained enough vaccines to cover 3.76% of the population. However, these figures exclude the 680 million doses available for purchase by African Union members under agreements between the African Union and vaccine manufacturers; this scheme would correspond to a population coverage of approximately 34.54 per cent. .